Forbes reports that cardiologists and statisticians are arguing about whether the cholesterol drug Vytorin might increase the rate of cancer deaths. But experts on both sides of the argument agree on one thing: They don’t like the way the results were made public. Instead of appearing first in a medical journal where results are carefully [...] ...
Anytime
